Should we screen for lung cancer in Australia?

Hew, Mark; Stirling, Robert G; Abramson, Michael J

doi:10.5694/mja13.11158

Topics

In reply: We welcome the opportunity to respond to correspondence from Marshall and colleagues and Mitchell and colleagues about the impact of the National Lung Screening Trial (NLST)1 on three distinct issues: (i) current medical practice; (ii) developing public health policy; and (iii) implementation of future screening.

1 The Alfred, Melbourne, VIC.
2 School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic.

Correspondence: m.hew@alfred.org.au

Competing interests:

No relevant disclosures.

1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
2. Bach PB, Gould MK, Silvestri GA. Computed tomography screening for lung cancer. Ann Intern Med 2013; 159: 155-156.
3. Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet 2013; 382: 732-741.
4. Manser R, Lethaby A, Irving LB, et al. Screening for lung cancer. Cochrane Database Syst Rev 2013; (6): CD001991.
5. Hew M, Stirling RG, Abramson MJ. Should we screen for lung cancer in Australia [editorial]? Med J Aust 2013; 199: 82-83. <MJA full text>
6. Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975–2000. J Natl Cancer Inst 2012; 104: 541-548.

Online responses are no longer available. Please refer to our instructions for authors page for more information.